The company's performance in Q4 FY26 presents a stark contradiction: whilst revenue climbed 38.40% year-on-year to ₹3.28 crores, operational inefficiencies resulted in a net loss that widened significantly. The quarter-on-quarter comparison reveals even more concerning trends, with revenue declining 25.62% from ₹4.41 crores in Q3 FY26, whilst the company plunged from a profit of ₹0.24 crores to a loss of ₹0.74 crores.
What makes this performance particularly troubling is the company's inability to translate revenue growth into profitability. The operating margin excluding other income collapsed to -13.72% in Q4 FY26, compared to -10.97% in the same quarter last year, indicating that the company's cost structure has deteriorated despite higher sales volumes.
Financial Performance: A Tale of Revenue Growth Without Profitability
Unjha Formulations' Q4 FY26 results reveal a company struggling with fundamental operational challenges. Net sales for the quarter stood at ₹3.28 crores, representing a robust 38.40% increase from ₹2.37 crores in Q4 FY25. However, this revenue expansion failed to deliver bottom-line growth, as the company reported a net loss of ₹0.74 crores against a loss of ₹0.41 crores in the year-ago period.
The sequential performance was equally concerning. Revenue declined 25.62% quarter-on-quarter from ₹4.41 crores in Q3 FY26, whilst the company swung from a profit of ₹0.24 crores to a loss of ₹0.74 crores. This volatility in quarterly performance raises questions about the sustainability of the company's business model and its ability to maintain consistent operational execution.
| Quarter | Net Sales (₹ Cr) | QoQ Growth | YoY Growth | Net Profit (₹ Cr) | Operating Margin |
|---|---|---|---|---|---|
| Mar'26 | 3.28 | -25.62% | +38.40% | -0.74 | -13.72% |
| Dec'25 | 4.41 | +2.80% | +17.29% | 0.24 | 6.35% |
| Sep'25 | 4.29 | +18.84% | +13.49% | 0.82 | 18.41% |
| Jun'25 | 3.61 | +52.32% | — | 0.39 | 11.08% |
| Mar'25 | 2.37 | -36.97% | — | -0.41 | -10.97% |
| Dec'24 | 3.76 | -0.53% | — | 0.22 | 6.12% |
| Sep'24 | 3.78 | — | — | -0.11 | -2.91% |
The company's profitability metrics paint a particularly grim picture. The profit before depreciation, interest, and tax (PBDIT) excluding other income stood at -₹0.45 crores in Q4 FY26, marking the lowest level in recent quarters. The PAT margin collapsed to -22.56%, down from -17.30% in Q4 FY25, indicating that cost pressures are intensifying rather than abating.
Employee costs rose to ₹0.34 crores in Q4 FY26 from ₹0.36 crores in Q4 FY25, representing a relatively stable cost base. However, the company's inability to control other operating expenses in the face of revenue growth suggests deeper structural issues in its cost management framework.
Operational Challenges: The Profitability Conundrum
The most pressing concern for Unjha Formulations is its persistent inability to achieve sustainable profitability despite operating in the pharmaceutical sector, which typically enjoys healthy margins. The company's return on equity (ROE) of 33.12% in the latest period appears impressive on the surface, suggesting efficient use of shareholder capital. However, this metric must be viewed with caution given the company's negative earnings in the most recent quarter and extremely small equity base of ₹3.14 crores.
The company's average ROE over the longer term stands at 10.35%, whilst its average return on capital employed (ROCE) is 13.11%. Whilst these figures indicate reasonable capital efficiency historically, they mask the volatility and inconsistency in quarterly performance that has characterised recent periods. The latest ROCE of 16.80% suggests improved capital deployment, but this improvement has not translated into consistent profitability.
Critical Operational Red Flags
Margin Collapse: Operating margin of -13.72% in Q4 FY26 represents the lowest level in the company's recent history, indicating severe cost control issues.
Earnings Quality: The company reported operating losses in Q4 FY26 despite year-on-year revenue growth of 38.40%, suggesting that growth is coming at an unsustainable cost.
Sequential Deterioration: The swing from a profit of ₹0.24 crores in Q3 FY26 to a loss of ₹0.74 crores in Q4 FY26 raises serious questions about operational stability.
From a balance sheet perspective, Unjha Formulations maintains a debt-free status with zero long-term borrowings as of March 2025. The company's net debt to equity ratio of -0.20 indicates it is a net cash company, which provides some financial flexibility. However, with shareholder funds of just ₹3.14 crores and reserves of -₹1.34 crores, the company has limited financial cushion to absorb continued losses.
The company's current assets stood at ₹3.35 crores against current liabilities of ₹1.41 crores as of March 2025, providing a current ratio of approximately 2.4x, which suggests adequate short-term liquidity. However, the deteriorating profitability trend could quickly erode this liquidity position if losses continue at the current pace.
Pharmaceutical Sector Context: Underperformance Against Industry Peers
Unjha Formulations operates in the pharmaceuticals and biotechnology sector, which has demonstrated resilience with the industry delivering an 11.82% return over the past year. In stark contrast, Unjha Formulations' stock has declined 13.08% over the same period, resulting in an underperformance of 24.90 percentage points against its sector peers.
The company's specialisation in Isabgol (Psyllium) formulations represents a niche within the broader pharmaceutical market. Whilst this focus allows for differentiation, it also exposes the company to concentration risk and limits its ability to diversify revenue streams. The volatility in quarterly revenue suggests that demand for these products may be seasonal or subject to significant fluctuations.
Industry Positioning: A Struggling Micro-Cap Player
With a market capitalisation of just ₹9.00 crores, Unjha Formulations ranks as a micro-cap company in the pharmaceutical sector. This small size limits its ability to achieve economies of scale, negotiate favourable terms with suppliers, and invest in research and development or capacity expansion. The company's inability to translate revenue growth into profitability suggests it lacks the operational leverage typically enjoyed by larger pharmaceutical manufacturers.
Peer Comparison: Valuation Without Justification
Comparing Unjha Formulations to its pharmaceutical sector peers reveals a company trading at seemingly attractive valuation multiples that may not be justified by its operational performance. The company's price-to-earnings ratio of 8.62x appears modest compared to the broader pharmaceutical sector's average P/E of 35x. However, this comparison is misleading given the company's recent losses and inconsistent profitability.
| Company | P/E (TTM) | P/BV | ROE % | Debt/Equity |
|---|---|---|---|---|
| Unjha Formul. | 8.62 | 2.85 | 10.35% | -0.20 |
| Parmax Pharma | NA (Loss Making) | -2.40 | 0.0% | -2.36 |
| Beryl Drugs | 1019.41 | 1.07 | 4.99% | 0.34 |
| Colinz Labs | 23.10 | 1.19 | 4.90% | -0.68 |
| Vivanza Biosci. | 18.30 | 1.68 | 10.64% | 2.32 |
| Decipher Labs | NA (Loss Making) | 0.38 | 14.54% | -0.02 |
Unjha Formulations' price-to-book value of 2.85x stands significantly above most of its micro-cap pharmaceutical peers, with only Parmax Pharma showing a negative P/BV due to its loss-making status. This premium valuation appears unjustified given the company's deteriorating profitability and operational challenges. The company's ROE of 10.35% places it in the middle of the peer group, but this metric is heavily influenced by the small equity base and recent volatility in earnings.
The debt-free status (debt-to-equity of -0.20) represents one of Unjha Formulations' few competitive advantages relative to peers. However, this conservative financial structure has not translated into superior operational performance or shareholder returns, as evidenced by the stock's significant underperformance against both the sector and broader market indices.
Valuation Analysis: Expensive Despite Operational Struggles
The company's current valuation assessment of "VERY EXPENSIVE" appears paradoxical given its micro-cap status and operational challenges. This classification stems from the stock's price-to-book value of 2.85x, which represents a significant premium to book value despite questionable earnings quality and sustainability.
At the current price of ₹20.00, the stock trades 34.21% below its 52-week high of ₹30.40 but remains 7.53% above its 52-week low of ₹18.60. The valuation grade history shows the stock transitioned from "Very Attractive" to "Very Expensive" within a matter of months during 2025, reflecting the volatile nature of micro-cap pharmaceutical stocks and the challenges in assigning fair value to companies with inconsistent earnings.
The company's EV/EBITDA multiple of 7.50x and EV/Sales of 0.57x appear reasonable on a standalone basis. However, these metrics must be interpreted with caution given the company's negative operating margins in the most recent quarter. The PEG ratio of 0.13x suggests the stock is undervalued relative to growth expectations, but this metric has limited relevance given the inconsistency in earnings growth and the recent swing to losses.
Shareholding Pattern: Stable but Concerning Institutional Absence
The shareholding pattern of Unjha Formulations reveals a highly concentrated ownership structure with minimal institutional participation. Promoter holding has remained stable at 36.92% across the last five quarters, with no sequential changes. The remaining 63.08% is classified as non-institutional holdings, suggesting the stock is primarily held by retail investors and high-net-worth individuals.
| Category | Mar'26 | Dec'25 | Sep'25 | Jun'25 | QoQ Change |
|---|---|---|---|---|---|
| Promoter | 36.92% | 36.92% | 36.92% | 36.92% | 0.00% |
| FII | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Mutual Funds | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Insurance | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Other DII | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Non-Institutional | 63.08% | 63.08% | 63.08% | 63.08% | 0.00% |
The complete absence of foreign institutional investors (FIIs), mutual funds, insurance companies, and other domestic institutional investors (DIIs) is a significant red flag. This lack of institutional participation suggests that sophisticated investors have avoided the stock, likely due to concerns about liquidity, governance, operational performance, or growth prospects. The zero institutional holding also means the stock lacks the support and stability that institutional ownership typically provides.
On a positive note, there is no promoter pledging, which eliminates one potential source of risk. However, the stable promoter holding at 36.92% raises questions about why promoters have not increased their stake given the stock's decline from its 52-week high, which could signal a lack of confidence in the company's near-term prospects.
Stock Performance: Severe Underperformance Across All Timeframes
Unjha Formulations' stock performance has been dismal across most timeframes, with the stock significantly underperforming both the Sensex and its pharmaceutical sector peers. Over the past year, the stock has declined 13.08% compared to the Sensex's decline of 8.52%, resulting in negative alpha of 4.56 percentage points.
| Period | Stock Return | Sensex Return | Alpha |
|---|---|---|---|
| 1 Week | -4.76% | -0.92% | -3.84% |
| 1 Month | -4.53% | -4.05% | -0.48% |
| 3 Months | -12.93% | -10.05% | -2.88% |
| 6 Months | -22.18% | -11.05% | -11.13% |
| YTD | -20.00% | -11.62% | -8.38% |
| 1 Year | -13.08% | -8.52% | -4.56% |
| 2 Years | -34.15% | +1.77% | -35.92% |
| 3 Years | +53.85% | +22.60% | +31.25% |
| 5 Years | +130.15% | +50.05% | +80.10% |
The underperformance has been particularly severe over the past six months, with the stock declining 22.18% compared to the Sensex's 11.05% decline, resulting in negative alpha of 11.13 percentage points. Year-to-date, the stock is down 20.00%, significantly worse than the Sensex's 11.62% decline.
The two-year performance is especially concerning, with the stock down 34.15% whilst the Sensex has gained 1.77%, resulting in a staggering negative alpha of 35.92 percentage points. This severe underperformance reflects the market's loss of confidence in the company's ability to deliver sustainable profitability and growth.
From a technical perspective, the stock is currently in a bearish trend, having changed to bearish from mildly bearish on May 12, 2026. The stock trades below all key moving averages—5-day (₹20.01), 20-day (₹20.84), 50-day (₹20.60), 100-day (₹21.89), and 200-day (₹23.41)—indicating sustained selling pressure and lack of buying interest.
Investment Thesis: Multiple Warning Signals Flash Red
The investment thesis for Unjha Formulations is severely compromised by multiple structural and operational challenges. The company's proprietary Mojo Score stands at just 27 out of 100, placing it firmly in the "STRONG SELL" category. This poor score reflects the convergence of negative factors across valuation, quality, financial trends, and technical indicators.
The quality assessment of "BELOW AVERAGE" is based on the company's weak long-term financial performance, with average ROCE of 13.11% and average ROE of 10.35% falling short of industry standards. The financial trend is classified as "FLAT" for Q4 FY26, with the company reporting its lowest operating profit and profit before tax in recent quarters despite revenue growth.
Key Strengths & Risk Factors
Key Strengths
- Debt-Free Balance Sheet: Zero long-term debt provides financial flexibility and eliminates interest burden.
- Niche Market Focus: Specialisation in Isabgol formulations offers differentiation in the pharmaceutical market.
- No Promoter Pledging: Zero pledged shares indicate promoter confidence and reduce governance risks.
- Strong Latest ROE: Recent ROE of 33.12% demonstrates efficient capital deployment when profitable.
- Revenue Growth: Q4 FY26 revenue grew 38.40% year-on-year, indicating market demand for products.
Key Concerns
- Persistent Losses: Net loss of ₹0.74 crores in Q4 FY26, widening from ₹0.41 crores in Q4 FY25.
- Negative Operating Margins: Operating margin of -13.72% indicates severe cost control issues.
- Zero Institutional Holding: Complete absence of FIIs, mutual funds, and other institutional investors.
- High Volatility: Stock volatility of 56.94% with beta of 1.50 indicates excessive risk.
- Severe Underperformance: Stock down 13.08% over one year vs sector gain of 11.82%.
- Micro-Cap Constraints: Market cap of ₹9.00 crores limits operational scale and investor interest.
- Inconsistent Quarterly Performance: Extreme volatility in quarterly results undermines predictability.
Outlook: What to Watch
Positive Catalysts
- Sustained revenue growth across multiple quarters
- Achievement of positive operating margins
- Return to consistent quarterly profitability
- Institutional investor participation
- Expansion of product portfolio beyond Isabgol formulations
Red Flags
- Continued quarterly losses despite revenue growth
- Further deterioration in operating margins
- Sequential revenue decline continuing beyond Q4 FY26
- Erosion of cash position due to sustained losses
- Continued absence of institutional investors
- Break below ₹18.60 (52-week low) on high volumes
The Verdict: Operational Turmoil Justifies Strong Sell Rating
Score: 27/100
For Fresh Investors: Avoid initiating any position. The company's deteriorating profitability, negative operating margins, and complete absence of institutional support make it unsuitable for investment. The micro-cap nature and high volatility add excessive risk without corresponding return potential.
For Existing Holders: Consider exiting positions at current levels or on any technical bounce towards ₹21-22 levels. The widening losses despite revenue growth indicate fundamental operational issues that may take considerable time to resolve. The bearish technical trend and sustained underperformance suggest further downside risk.
Rationale: Unjha Formulations' Q4 FY26 results reveal a company struggling with fundamental profitability challenges despite operating in a growing pharmaceutical sector. The combination of negative operating margins, widening losses, zero institutional participation, severe market underperformance, and bearish technical indicators creates an unfavourable risk-reward profile that justifies the Strong Sell rating.
Note— ROCE= (EBIT - Other income)/(Capital Employed - Cash - Current Investments)
⚠️ Investment Disclaimer
This article is for educational and informational purposes only and should not be construed as financial advice. Investors should conduct their own due diligence, consider their risk tolerance and investment objectives, and consult with a qualified financial advisor before making any investment decisions.
